Chemistry Reference
In-Depth Information
Table 3.6 Main randomized Controlled Clinical studies using Fructan Prebiotic For Effect In Patients With Colonic Polyps And/or
Cancer
Prebiotic Type,
Consumption
Method/end
Points
subjects
study Design
Main results
ref.
Colon cancer with
“curative resection” (
n
=
34)
Polypectomized patients
(
n
= 40)
randomized
double-blind,
placebo-controlled
trial
encapsulated bacteria
a
and 10 g of inulin
enriched with
oligofructose (syn group)
or placebo once daily
Modulation of
immune
functions
•
in the cancer group, syn resulted
roller
et al.,
2007
in an increased capacity of PbMC
to produce interferon-gamma
(
P
< 0.05)
in the polyp group, iL-2 secretion
•
by activated PbMC
b
increased
(
P
< 0.05)
Colon cancer (
n
= 37
Polypectomized (
n
= 43)
randomized,
double-blind,
placebo-controlled
trial (phase 2
study)
synbiotic food composed
of the prebiotic syn1—a
mixture of short-chain
and long-chain inulin
(syn1)—and probiotics
Lgg and bb12
c
vs.
placebo for 12 weeks
reduction in
cancer risk
biomarkers
in stools
and
intestinal
mucosa
in all patients:
increase of
rafter
et al.,
2007
•
Biidobacterium
and
Lactobacillus
decrease of
•
Clostridium
perfringens
reduction in colorectal
•
proliferation and the capacity of
fecal water to induce necrosis in
colonic cells
in polypectomized patients:
improvement of epithelial barrier
•
function
decreased exposure to
•
genotoxins
Prevention of an increased
•
secretion of iL-2 by peripheral
blood mononuclear cells
in cancer patients:
increase in interferon-gamma
•
production
